Last close As at 06/08/2026
EUR0.61
— 0.00 (0.00%)
Market capitalisation
EUR35m
Research: TMT
Claranova has reported another strong quarter, with organic constant currency revenue growth of 33% y-o-y in Q319, maintaining the same rate of growth as in H119. Geographic and product expansion are driving PlanetArt growth, while the recent acquisitions by Avanquest have reinvigorated the division. We have revised our revenue forecasts up to reflect stronger than expected growth, although this has a minimal impact at the EBITDA level.
Claranova |
Growth strategy paying off |
Q3 revenue update |
Software & comp services |
15 May 2019 |
Share price performance
Business description
Next events
Analyst
Claranova is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||
Claranova has reported another strong quarter, with organic constant currency revenue growth of 33% y-o-y in Q319, maintaining the same rate of growth as in H119. Geographic and product expansion are driving PlanetArt growth, while the recent acquisitions by Avanquest have reinvigorated the division. We have revised our revenue forecasts up to reflect stronger than expected growth, although this has a minimal impact at the EBITDA level.
Year end |
Revenue (€m) |
EBITDA |
PBT* |
EPS* |
DPS |
P/E |
06/17 |
130.2 |
(5.0) |
(6.6) |
(0.02) |
0.0 |
N/A |
06/18 |
161.5 |
3.9 |
3.1 |
0.01 |
0.0 |
133.2 |
06/19e |
253.9 |
18.0 |
14.6 |
0.03 |
0.0 |
29.0 |
06/20e |
317.9 |
30.0 |
26.7 |
0.05 |
0.0 |
17.1 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Q319: 33% organic revenue growth
Claranova continued to enjoy strong organic growth during Q319. Reported group revenues increased 69% y-o-y; excluding the impact of the Avanquest acquisitions and currency effects, group revenue grew 33% y-o-y. European expansion and the launch of the Photo Tiles product in H119 resulted in reported growth of 49% for the PlanetArt business (41% on a constant currency basis). The new monetisation methods from the acquired businesses in the Avanquest division have benefited both the acquired and existing businesses, driving organic growth of 22% for both parts of the division. At less than 2% of Q3 group revenues, myDevices is not yet making a material contribution but the development of new routes to market, including a recent partnership with Microsoft, provides the foundation for growth.
Upgrading revenue forecasts
On the basis of better than expected growth in PlanetArt and Avanquest revenues in Q3, we have increased our FY19 revenue forecast by 2.0% and FY20 by 3.6%. As some of this upside is due to currency translation and we assume the company has increased marketing spend to acquire more customers, we make minimal changes at the EBITDA and EPS level.
Valuation: Small increase from revenue upside
Reflecting the different business models and minority interests for each division, we continue to use a sum-of-the-parts approach to valuation. Based purely on peer group averages per division, we calculate a fair value of €1.17 per share. However, once multiples are adjusted to reflect our views on the growth and profitability of each division, this increases to €1.31 per share (up from €1.28, driven by higher revenue estimates). Milestones that could provide upside to our forecasts include: successful adoption of FreePrints in India; growth of the acquired Adaware business; and distributors reselling the myDevices platform in the US and China.
Q3 revenue update confirms strong organic growth
Claranova’s Q3 revenue update confirms that PlanetArt and Avanquest are seeing continued strong organic growth, with some benefit from the stronger dollar in the quarter. Group constant currency organic growth of 33% compares to 33% in Q219 and 32% in Q119.
Exhibit 1: Q3 revenues by division
€m |
Q319 |
Q318 |
y-o-y |
y-o-y |
y-o-y |
reported |
organic |
organic constant currency |
|||
PlanetArt |
34.9 |
23.4 |
49% |
49% |
41% |
Avanquest |
20.4 |
8.6 |
136% |
22% |
20% |
myDevices |
0.9 |
1.2 |
(26%) |
(26%) |
(31%) |
Total |
56.2 |
33.2 |
69% |
39% |
33% |
Source: Claranova
PlanetArt: Growth from product and geographic expansion
The division saw reported growth of 49% in Q3, with 8% of this due to the weaker euro versus the dollar. Constant currency growth of 41% compares to 37% in Q219 and 44% in Q119. While the division saw growth across the board, the company pointed to strong demand in Europe. The launch of the app in Belgium and Netherlands earlier in the quarter was well received and the Photo Tiles product, which is available in five of the 10 countries in which PlanetArt is present, also contributed to growth.
Avanquest: Reinvigorated by acquired businesses
The original Avanquest business saw 22% growth y-o-y, accelerating from the 16% growth reported in Q219 and 3% in Q119. More business is shifting to subscription rather than upfront licensing, providing recurring revenues and better predictability. The acquired businesses also saw 22% organic growth in the quarter, versus 23% for H119. The company’s strategy has been to increase monetisation of visitors to its sites. The acquired businesses, particularly Adaware, bring new methods of monetisation to the division – with each visitor on average generating more revenue for Avanquest, this provides additional funds for marketing, which in turn attracts new visitors to Avanquest sites.
myDevices: Building out routes to market
myDevices reported a 26% revenue decline compared to Q318; however, in Q318 the division benefited from a one-off payment of $1m from Sprint. Excluding this, the rest of the division grew 129% y-o-y. In February, myDevices signed a partnership with Microsoft to provide IoT data analytics tools to Azure customers. Added to partnerships signed with Sprint, Dr Peng, Alibaba Cloud and Ingram Micro, myDevices now has a variety of routes to market in the US, Europe and China.
Changes to forecasts
We have revised our forecasts to reflect stronger than expected revenue growth in PlanetArt and Avanquest. As some of this was due to currency translation effects and we expect some of the remaining growth will have resulted from higher marketing spend, we have made minimal changes at the EBITDA level. We note that PlanetArt has not yet seen a material contribution to revenues from India, and Avanquest has yet to launch Payaware (a new secure payments solution) – both are potential growth drivers for FY20.
Exhibit 2: Changes to forecasts
€m |
FY19e |
FY19e |
FY20e |
FY20e |
|||||
Old |
New |
Change |
y-o-y |
Old |
New |
Change |
y-o-y |
||
Revenues |
248.9 |
253.9 |
2.0% |
57.2% |
306.8 |
317.9 |
3.6% |
25.2% |
|
EBITDA |
18.0 |
18.0 |
0.2% |
362.6% |
29.8 |
30.0 |
0.7% |
66.3% |
|
EBITDA margin |
7.2% |
7.1% |
-1.7% |
4.7% |
9.7% |
9.4% |
-2.9% |
2.3% |
|
Normalised operating profit |
17.4 |
17.4 |
0.2% |
412.9% |
29.3 |
29.5 |
0.7% |
69.2% |
|
Normalised operating profit margin |
7.0% |
6.9% |
-0.1% |
4.8% |
9.6% |
9.3% |
-0.3% |
2.4% |
|
Reported operating profit |
12.3 |
12.3 |
0.3% |
N/A |
27.1 |
27.3 |
0.7% |
121.2% |
|
Reported operating margin |
4.9% |
4.9% |
-0.1% |
8.6% |
8.8% |
8.6% |
-0.2% |
3.7% |
|
Normalised PBT |
14.6 |
14.6 |
0.3% |
372.3% |
26.5 |
26.7 |
0.8% |
82.1% |
|
Reported PBT |
9.5 |
9.5 |
0.4% |
N/A |
24.3 |
24.5 |
0.8% |
156.4% |
|
Normalised net income |
11.5 |
11.6 |
0.5% |
340.7% |
19.5 |
19.6 |
0.8% |
69.5% |
|
Reported net income |
7.6 |
7.6 |
0.7% |
N/A |
17.8 |
17.9 |
0.9% |
134.4% |
|
Normalised basic EPS (€) |
0.03 |
0.03 |
0.5% |
342.6% |
0.05 |
0.05 |
0.8% |
69.5% |
|
Normalised diluted EPS (€) |
0.03 |
0.03 |
0.5% |
359.5% |
0.05 |
0.05 |
0.8% |
69.5% |
|
Reported basic EPS (€) |
0.02 |
0.02 |
0.7% |
N/A |
0.05 |
0.05 |
0.9% |
134.3% |
|
Net debt/(cash) |
(16.6) |
(17.2) |
4.1% |
-54.0% |
(43.0) |
(44.6) |
3.8% |
158.7% |
Source: Edison Investment Research
Exhibit 3: Financial summary
€m |
2015 |
2016 |
2017 |
2018 |
2019e |
2020e |
||
30-June |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
INCOME STATEMENT |
||||||||
Revenue |
|
|
93.1 |
117.4 |
130.2 |
161.5 |
253.9 |
317.9 |
EBITDA |
|
|
(6.8) |
(9.2) |
(5.0) |
3.9 |
18.0 |
30.0 |
Normalised operating profit |
|
|
(11.4) |
(16.0) |
(5.8) |
3.4 |
17.4 |
29.5 |
Amortisation of acquired intangibles |
0.0 |
0.0 |
0.0 |
0.0 |
(0.2) |
(0.2) |
||
Exceptionals |
15.6 |
(10.0) |
0.4 |
(2.4) |
(4.2) |
0.0 |
||
Share-based payments |
(0.0) |
(0.1) |
(4.8) |
(7.1) |
(0.7) |
(2.0) |
||
Reported operating profit |
4.2 |
(26.1) |
(10.1) |
(6.1) |
12.3 |
27.3 |
||
Net Interest |
1.1 |
(1.7) |
(0.9) |
(0.3) |
(2.8) |
(2.8) |
||
Joint ventures & associates (post tax) |
0.0 |
(0.0) |
0.0 |
0.0 |
0.0 |
0.0 |
||
Exceptionals |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Profit Before Tax (norm) |
|
|
(10.3) |
(17.7) |
(6.6) |
3.1 |
14.6 |
26.7 |
Profit Before Tax (reported) |
|
|
5.3 |
(27.8) |
(11.0) |
(6.4) |
9.5 |
24.5 |
Reported tax |
(0.6) |
(0.8) |
(0.4) |
(1.8) |
(2.2) |
(5.6) |
||
Profit After Tax (norm) |
(10.9) |
(18.5) |
(7.0) |
2.4 |
11.3 |
20.5 |
||
Profit After Tax (reported) |
4.7 |
(28.6) |
(11.4) |
(8.2) |
7.3 |
18.8 |
||
Minority interests |
(8.1) |
0.0 |
0.3 |
0.2 |
0.3 |
(0.9) |
||
Discontinued operations |
(3.2) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Net income (normalised) |
(18.9) |
(18.5) |
(6.7) |
2.6 |
11.6 |
19.6 |
||
Net income (reported) |
(6.5) |
(28.6) |
(11.0) |
(7.9) |
7.6 |
17.9 |
||
Basic average number of shares outstanding (m) |
58 |
375 |
375 |
394 |
392 |
392 |
||
EPS - basic normalised (€) |
|
|
(0.33) |
(0.05) |
(0.02) |
0.01 |
0.03 |
0.05 |
EPS - diluted normalised (€) |
|
|
(0.33) |
(0.05) |
(0.02) |
0.01 |
0.03 |
0.05 |
EPS - basic reported (€) |
|
|
(0.11) |
(0.08) |
(0.03) |
(0.02) |
0.02 |
0.05 |
Dividend (€) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
||
Revenue growth (%) |
#DIV/0! |
26.1 |
10.9 |
24.0 |
57.2 |
25.2 |
||
EBITDA Margin (%) |
-7.3 |
-7.9 |
-3.8 |
2.4 |
7.1 |
9.4 |
||
Normalised Operating Margin |
-12.3 |
-13.7 |
-4.4 |
2.1 |
6.9 |
9.3 |
||
BALANCE SHEET |
||||||||
Fixed Assets |
|
|
15.7 |
3.0 |
2.0 |
1.3 |
74.6 |
74.2 |
Intangible Assets |
12.0 |
1.5 |
0.9 |
0.5 |
73.0 |
72.6 |
||
Tangible Assets |
0.6 |
0.5 |
0.3 |
0.2 |
1.0 |
1.0 |
||
Investments & other |
3.1 |
1.1 |
0.7 |
0.6 |
0.6 |
0.6 |
||
Current Assets |
|
|
48.0 |
25.5 |
28.1 |
79.1 |
65.0 |
96.3 |
Stocks |
5.9 |
5.0 |
3.7 |
3.7 |
7.0 |
8.7 |
||
Debtors |
4.8 |
4.7 |
4.3 |
4.9 |
8.3 |
10.5 |
||
Cash & cash equivalents |
30.5 |
11.1 |
17.1 |
65.7 |
44.9 |
72.3 |
||
Other |
6.9 |
4.7 |
2.9 |
4.8 |
4.8 |
4.8 |
||
Current Liabilities |
|
|
(32.0) |
(25.3) |
(28.1) |
(37.2) |
(47.0) |
(57.0) |
Creditors |
(26.9) |
(24.5) |
(26.6) |
(35.4) |
(45.2) |
(55.2) |
||
Tax and social security |
(0.3) |
(0.0) |
(0.3) |
(1.7) |
(1.7) |
(1.7) |
||
Short term borrowings |
(4.8) |
(0.7) |
(1.1) |
(0.1) |
(0.1) |
(0.1) |
||
Other |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Long Term Liabilities |
|
|
(2.4) |
(1.1) |
(0.7) |
(29.0) |
(69.7) |
(69.7) |
Long term borrowings |
(1.8) |
(0.6) |
0.0 |
(28.1) |
(27.6) |
(27.6) |
||
Other long term liabilities |
(0.7) |
(0.5) |
(0.7) |
(0.9) |
(42.1) |
(42.1) |
||
Net Assets |
|
|
29.3 |
2.1 |
1.3 |
14.2 |
22.9 |
43.8 |
Minority interests |
0.0 |
0.0 |
(0.1) |
(1.8) |
(4.1) |
(5.0) |
||
Shareholders' equity |
|
|
29.3 |
2.1 |
1.2 |
12.5 |
18.9 |
38.8 |
CASH FLOW |
||||||||
Op Cash Flow before WC and tax |
(6.8) |
(9.2) |
(5.0) |
3.9 |
18.0 |
30.0 |
||
Working capital |
0.4 |
2.5 |
6.8 |
7.9 |
3.1 |
6.1 |
||
Exceptional & other |
(3.8) |
(4.3) |
(2.2) |
(5.2) |
(8.4) |
0.0 |
||
Tax |
0.3 |
(0.3) |
(0.0) |
(1.2) |
(2.2) |
(5.6) |
||
Net operating cash flow |
|
|
(9.8) |
(11.3) |
(0.4) |
5.5 |
10.6 |
30.5 |
Capex |
(4.4) |
(0.9) |
(0.2) |
(0.1) |
(2.3) |
(0.3) |
||
Acquisitions/disposals |
10.8 |
(0.4) |
3.6 |
14.2 |
(23.8) |
0.0 |
||
Net interest |
(0.9) |
(0.1) |
(0.0) |
(0.3) |
(2.8) |
(2.8) |
||
Equity financing |
33.2 |
(5.1) |
1.9 |
2.0 |
(1.9) |
0.0 |
||
Dividends |
0.0 |
2.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Other |
0.1 |
0.1 |
0.1 |
(1.1) |
0.0 |
0.0 |
||
Net Cash Flow |
29.0 |
(15.7) |
5.0 |
20.1 |
(20.3) |
27.4 |
||
Opening net debt/(cash) |
|
|
18.0 |
(23.9) |
(9.8) |
(16.0) |
(37.5) |
(17.2) |
FX |
0.1 |
(0.1) |
(0.6) |
0.4 |
0.0 |
0.0 |
||
Other non-cash movements |
12.6 |
1.7 |
1.8 |
1.1 |
0.0 |
0.0 |
||
Closing net debt/(cash) |
|
|
(23.9) |
(9.8) |
(16.0) |
(37.5) |
(17.2) |
(44.6) |
|
Source: Company data, Edison Investment Research |
||||||||
|
|
Research: Healthcare
PDL BioPharma reported Q119 revenues of $38.9, up 1.0% compared to Q118. Going forward, the company indicated that it would be working intensely to maximize its investment in Evofem, a women’s health company that is preparing to submit an NDA for Amphora, a non-hormonal female contraceptive, in Q419 with a launch expected in H120. The company also announced that it has bought back $80.3m worth of its shares since the beginning of the $100m stock repurchase program announced last September.